Paul C. Langley, PhD

home / authors / paul-c-langley-phd

Articles

Site Logo
February 1st 2000

Is Cost-Effectiveness Modeling Useful?

Paul C. Langley, PhD

Site Logo
January 1st 1999

The Cost Effectiveness of Patient-Applied Versus Provider-Administered Intervention Strategies for the Treatment of External Genital Warts

Paul C. Langley, PhD Stephen K. Tyring, MD, PhD Michael H. Smith, MS

Site Logo
April 1st 1998

Pharmacoeconomics Perspectives: Payers, Providers, and Patients

Paul C. Langley, PhD Nicolaas Otten, PharmD Peter Davey, MD James C. Bonnette, MD J. Russell Teagarden William F. McGhan, PharmD, PhD

Site Logo
July 1st 1997

Managed Care Guidelines for the Economic Evaluation of Pharmaceuticals

Paul C. Langley, PhD Robert E. Martin, MS, RPh

Site Logo
September 1st 1996

Establishing the Basis for Successful Disease Management Contracting

Paul C. Langley, PhD Clare E. Langley-Hawthorne, LLB Robert E. Martin, RPh, MS Edward P. Armstrong, PharmD

Latest Updated Articles

FDA approval stamp | Image Credit: Surendra - stock.adobe.com
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
What We’re Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Program for Elderly Care; Health Care Not a Top Issue Among Voters
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Clinician giving patient a diagnosis | Image Credit: Pcess609 - stock.adobe.com
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Hurricane | Image credit: Satoshi Kina - stock.adobe.com
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Opdivo packaging | Image credit: Bristol Myers Squibb
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
ICYMI: Highlights From IMS 2024
Published: December 17th 2024 | Updated: December 22nd 2024
ICYMI: Highlights From IMS 2024

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo